Gaudium IVF Women Health IPO Listing at 5.06% Premium at ₹83 Per Share
- February 27, 2026
- Posted by: Ekta Dhawan
- Category: IPO
Gaudium IVF Women Health IPO Listing Today: The Gaudium IVF & Women Health IPO was subscribed 7.27 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 1.62 times, and non-institutional investors (NIIs) received 1.62 times. The retail quota of the issue was subscribed to 35.00%. Before delving deeper into the topic, go through the details of the Gaudium IVF & Women Health IPO.
Gaudium IVF Women Health IPO
It is a bookbuilding IPO of ₹165.00 crore, comprising an entirely fresh issue of 1.14 crore shares and an offer-for-sale of 0.95 crore shares. The issue will be listed on BSE and NSE on its tentative listing date, 27th February 2026. The Gaudium IVF & Women Health IPO date is fixed between 20th February 2026 and 24th February 2026. The face value of Gaudium IVF & Women Health shares stands at ₹10 per share, and the IPO Issue price band is set at ₹75 to ₹79 per share
| IPO Allotment Date | 25th February 2026 |
| IPO Open Date | 20th January 2026 |
| IPO Close Date | 24th February 2026 |
| Refund Initiation | 25th February 2026 |
| Issue Size | 2,08,86,200 shares(agg. up to ₹165 Cr) |
| Fresh Issue | 1,13,92,500 shares(agg. up to ₹90 Cr) |
| Offer for Sale | 94,93,700 shares of ₹5(agg. up to ₹75 Cr) |
| Face Value | ₹5 per share |
| Lot Size | 189 Shares |
| Issue Price | ₹75 to ₹79 per share |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE NSE |
| Listing Date | 27th February 2026 |
Gaudium IVF & Women Health Listing
On the BSE & NSE platforms, Gaudium IVF & Women Health shares are listed at ₹83 per share, reflecting a 5.06% Premium over the issue price of ₹79 per share.
About Gaudium IVF & Women Health Limited
Gaudium IVF & Women Health Incorporated in March 2015, Gaudium IVF and Women Health Limited have been involved in In Vitro Fertilisation (IVF) procedures across India and have extended their services to several states using a hub-and-spoke model of operation. The firm has more than thirty locations, consisting of seven hubs (centres) and twenty-eight spokes. The firm has formed a strategic alliance with Infertility Experts, referred to as Spokes, to attain the common goal of creating awareness about Assisted Reproductive Technology (ART) and In Vitro Fertilisation (IVF) procedures. The firm provides services to patients belonging to different nations, such as Canada, the United Kingdom, the United States of America, Kenya, South Africa, and Oman.
Gaudium IVF & Women Health Limited Financials
The company’s financial analysis is essential before applying for the Gaudium IVF & Women Health IPO. See the table for Gaudium IVF & Women Health Limited’s financials.
| Year Ended | 30th Sep 2025 (in cr.) | 31st March 2025 (in cr.) | 31st March 2024 (in cr.) | 31st March 2023 (in cr.) |
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Revenue | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| Net Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowings | 22.51 | 18.93 | 15.73 | 9.78 |
Explanation
Gaudium IVF & Women Health Limited’s revenue increased by 47.37% from ₹48.15 crores in March 2024 to ₹70.96 crores in March 2025. Moreover, the company’s PAT increased by 85.36% from ₹10.32 crores in March 2024 to ₹19.13 crores in March 2025.
Recent Articles
Kiaasa Retail IPO Listing Preview
Mobilise App Lab IPO Listing Preview
Yaap Digital IPO GMP & Subscription Status: Day 3
